Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

• Sponsor: Case Comprehensive Cancer Center (Other)
• Overall Status: Completed
• CT.gov ID: NCT01093586
• Collaborator: (none)
• Enrollment: 14
• Location: 1
• Arm: 1
• Duration (Months): 99
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from an unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and cyclosporine and mycophenolate mofetil after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well donor umbilical cord blood stem cell transplant works in treating patients with hematologic malignancies.

Condition or Disease	Intervention/Treatment	Phase
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Erythroleukemia (M6a); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Pure Erythroid Leukemia (M6b); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Erythroleukemia (M6); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia	Procedure: double-unit umbilical cord blood transplantation; Other: cytogenetic analysis; Procedure: bone marrow aspiration; Other: fluorescence in situ hybridization; Drug: busulfan; Drug: cyclophosphamide; Drug: anti-thymocyte globulin; Drug: methylprednisolone; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

1. To establish the day +180 overall survival after a myeloablative unrelated double unit UCBT in a single institution setting.

SECONDARY OBJECTIVES:

1. To determine the rates of hematologic and immune reconstitution in patients with high risk hematologic malignancies, who are undergoing myeloablative chemotherapy followed by infusion of double unit UCBT.

2. To determine the contribution of each umbilical cord unit to immune reconstitution with a focus on both initial (day +21 BM, and +28 PB) and sustained engraftment (day +100 BM; PB at +14, +21, +28, +35, +42, +60, +100, +180, +1 and 2 years).

3. To determine the probability of overall survival and disease free survival at one and two years.

4. To describe the incidence of disease recurrence at one and two years in patients post UCBT.

5. To describe the incidence of acute GVHD and chronic GVHD at 100 days and at one year, respectively.

6. To determine the incidence of day 100 and 180 treatment related mortality.

7. To determine the incidence of serious infectious complications in the first year after transplant.

8. To determine the incidence of donor-derived neutrophil and platelet recovery.

9. To determine the incidence of secondary lymphoproliferative diseases following transplantation with umbilical cord blood.

OUTLINE:

PREPARATIVE REGIMEN: Patients receive oral busulfan every 6 hours on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1.

TRANSPLANTATION: Patients undergo double-unit umbilical cord blood allogeneic stem cell transplantation on day 0.

GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally every 8 hours on days -3 to 45. After completion of study treatment, patients are followed periodically.

Study Design

• Study Type: Interventional
• Actual Enrollment: 14 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies
• Study Start Date: Sep 1, 2007
• Actual Primary Completion Date: Dec 1, 2015
• Actual Study Completion Date: Dec 1, 2015

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Arm I PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.

Procedure: double-unit umbilical cord blood transplantation; Undergo transplantation; Other: cytogenetic analysis; Correlative studies; Procedure: bone marrow aspiration; Correlative studies; Other: fluorescence in situ hybridization; Correlative studies; Other Names: fluorescence in situ hybridization (FISH) ; Drug: busulfan; Given orally; Other Names: BSF BU Misulfan Mitosan Myeloleukon Myelosan ; Drug: cyclophosphamide; Given IV; Other Names: CPM CTX Cytoxan Endoxan Endoxana Enduxan ; Drug: anti-thymocyte globulin; Given IV; Other Names: ATG ATGAM lymphocyte immune globulin Thymoglobulin ; Drug: methylprednisolone; Given IV; Other Names: A-MethaPred Depo-Medrol Medrol MePRDL Solu-Medrol Wyacort ; Drug: cyclosporine; Given IV; Other Names: 27-400 ciclosporin cyclosporin cyclosporin A CYSP Sandimmune ; Drug: mycophenolate mofetil; Given orally or IV; Other Names: Cellcept MMF ; Other: flow cytometry; Correlative studies; Procedure: allogeneic hematopoietic stem cell transplantation; Undergo transplantation

Outcome Measures

Primary Outcome Measures

1. Overall Survival [On day +180]

   Number of participants alive at 180 days post engraftment.

Secondary Outcome Measures

1. Hematologic Engraftment [On day +42]

   Number of participants that were able to complete engraftment by day 42.

2. Overall Survival [At 1 year]

   Number of participants that were alive.

3. Overall Survival [At 2 years]

   Number of participants that were alive.

4. Disease Free [At 1 year]

   Number of participants that were disease free

5. Disease Free [At 2 years]

   Number of participants that were disease free

6. Recurrence or Relapse [one year in patients post UCBT]

   Number of subjects that had disease recurrence

7. Recurrence or Relapse [two years post transplant]

   Number of subjects that had disease recurrence

8. Transplant Related Mortality [On day 100 post transplant]

   Number of subjects that died because of transplant

9. Transplant Related Mortality [On day 180 post transplant]

   Number of subjects that died because of transplant

10. Occurrence of Serious Infections [1 year]

    Number of participants that had infections

11. Immune Reconstitution [Periodically for 2 years]

    Immunodificency panel to see recovery of immune system. Number of participants that recovered.

12. Toxicity Related to UCB Transplantation and Cytoreduction as Assessed by CTC v3.0 [by day +42]

    Number of participants that experienced toxicity related to the transplant

13. Incidence of Acute Graft-versus-host Disease (GVHD) [At 100 days]

    Number of participants that had acute GVHD

14. Incidence of Chronic GVHD [At 1 year]

    Number of participants that have chronic GVHD. Chronic GVHD will be diagnosed and graded on clinical and histological criteria from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 12 Years to 64 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients will be diagnosed with one of the following hematological malignancies: acute myelogenous leukemia (AML), acute lymphoblastic leukemia, non-Hodgkin's lymphoma, myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), and myeloproliferative and lymphoproliferative disorders

• AML--First remission (CR1) with high risk features including a known prior diagnosis of myelodysplasia (MDS); therapy related AML; white cell count at presentation > 100,000; presence of extramedullary leukemia at diagnosis; unfavorable AML subtype (M0, M5-M7); poor cytogenetic markers (abnormalities of chromosome 5, 7 or 8, 11q23, Philadelphia chromosome, complex karyotype)

• AML--Second remission (CR2) or subsequent remission

• AML--Relapse/Persistent Disease with < 20% bone marrow blasts

• ALL--First remission (CR1) at high risk for relapse as defined by: B cell ALL white blood cell count (WBC) at presentation > 30,000 (T cell ALL WBC > 100,000); presence of high-risk cytogenetic abnormality such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23), t(8;14)

• ALL--Second remission (CR2) or subsequent remission

• ALL--Relapse/Persistent Disease with < 20% bone marrow blasts

• Non-Hodgkin Lymphoma--Induction failure or relapse and sensitive to most recent chemotherapy

• MDS--Low or Intermediate-1 International Prognostic Scoring System (IPSS) score with: life-threatening cytopenia(s); and/or red cell or platelet transfusion dependence

• MDS--ANC < 500, recurrent infections, PRBC transfusions > 2 units/month, poor risk cytogenetics, platelet transfusion dependence

• MDS--Intermediate-2 or High IPSS score

• CML--Chronic phase I (CP1) and resistant to or intolerant of tyrosine kinase inhibitors (i.e. imatinib, dasatinib, etc.)

• CML--CP2 or subsequent chronic phase, including chronic phase achieved after induction therapy for blast crisis

• Myeloproliferative and lymphoproliferative disorders--eligibility to be determined by a consensus of the physicians on the Case Comprehensive Cancer Center Leukemia/Lymphoma Multidisciplinary Committee

• Myeloproliferative and lymphoproliferative disorders--must have evidence of disease acceleration to be a candidate for umbilical cord blood transplant; myeloproliferative disorders eligible for transplant include chronic myelomonocytic leukemia (CMML) with high IPSS score and myelofibrosis

• Myeloproliferative and lymphoproliferative disorders--potential lymphoproliferative disorders eligible for transplant include chronic lymphocytic leukemia, prolymphocytic leukemia, and large granular lymphocytic leukemia

• Good performance status: Karnofsky >= 70 % or ECOG 0-1

• Calculated creatinine clearance >= 60 mL/min, or measured creatinine clearance >= 60 mL/min (by 24-hour urine collection) if creatinine >= 1.5 or history of renal dysfunction

• Hepatic Transaminases < 4 x upper limit normal (ULN); total bilirubin < 2.5 mg/dL, unless the patient has a history of benign congenital hyperbilirubinemia (Gilbert's syndrome)

• Normal cardiac function by echocardiogram or radionuclide scan, (left ventricular ejection fraction > 45%); if the left ventricular ejection fraction is between 40-50%, clearance by an adult cardiologist is required

• Pulmonary function tests demonstrating FEV1 > 60% of predicted for age

• Adults must have a DLCOva > 60% normal

• For patients unable to complete pulmonary function tests clearance by an adult pulmonologist is required

• Patients will be eligible for the clinical trial under the following conditions: they do NOT have an HLA-A/B/DR B1 identical RELATED bone marrow donor; they do NOT have a 6/6 HLA-identical matched unrelated adult donor; OR a matched related donor transplant is not in the best interest of the patient (i.e., patient's condition precludes waiting on the donor, too much time to prepare the donor, the donor is ineligible due to medical reasons, or in the case of high risk disease a related donor is not appropriated (syngeneic transplant); the decision must be agreed upon by the consensus of physicians on the Case Comprehensive Cancer Center Leukemia/Lymphoma Multidisciplinary Committee; OR their condition precludes waiting to search and find a donor in the National Marrow Donor Registry

Exclusion Criteria:

• Female patients who are pregnant or breast-feeding

• HIV or HTLV-1 positivity

• Any leukemia with a morphologic relapse or persistent disease in the BM with >= 20% blasts (cytogenetic relapse without morphologic evidence of relapse, or cytogenetic persistent disease is acceptable)

• Active extramedullary leukemia, including CNS disease

• Prior hematopoietic stem cell transplant (autologous or allogeneic)

• Uncontrolled infection

• Patient has an identical related bone marrow donor or a 6/6 HLA-identical matched unrelated donor

• Any patient who is unable to provide informed consent or comply with the requirements of the protocol

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center	Cleveland	Ohio	United States	44106

Sponsors and Collaborators

• Case Comprehensive Cancer Center

Investigators

• Principal Investigator: Brenda Cooper, MD, Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Case Comprehensive Cancer Center
• ClinicalTrials.gov Identifier: NCT01093586
• Other Study ID Numbers: CASE3Z07; NCI-2009-01319; CASE3Z07
• First Posted: Mar 26, 2010
• Last Update Posted: Jan 23, 2019
• Last Verified: Jan 1, 2019

• Additional relevant MeSH terms: Burkitt Lymphoma; Mycoses; Lymphoma; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Preleukemia; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Plasmablastic Lymphoma; Hematologic Neoplasms; Mycosis Fungoides; Leukemia, Myelomonocytic, Acute; Leukemia, Myelomonocytic, Chronic; Sezary Syndrome; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Leukemia, Myelomonocytic, Juvenile; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Chronic-Phase; Blast Crisis; Lymphomatoid Granulomatosis; Lymphoma, Extranodal NK-T-Cell; Leukemia, Prolymphocytic; Leukemia, Monocytic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Erythroblastic, Acute; Leukemia, Large Granular Lymphocytic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Myelodysplastic-Myeloproliferative Diseases; Syndrome; Recurrence; Cyclosporine; Mycophenolic Acid; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Cyclophosphamide; Busulfan; Cyclosporins; Thymoglobulin; Antilymphocyte Serum; Prednisolone hemisuccinate; Prednisolone phosphate

Study Results

Participant Flow

Recruitment Details	Participants recruited from medical hospital from 9/2007 thru 2/2013.

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Period Title: Overall Study
STARTED	14
COMPLETED	11
NOT COMPLETED	3

Baseline Characteristics

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Overall Participants	14
Age, Customized (Count of Participants)
10-19 yrs	2 14.3%
20-29 yrs	2 14.3%
30-39 yrs	3 21.4%
40-49 yrs	5 35.7%
50-59 yrs	2 14.3%
Sex: Female, Male (Count of Participants)
Female	8 57.1%
Male	6 42.9%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%
Not Hispanic or Latino	13 92.9%
Unknown or Not Reported	1 7.1%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	0 0%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	3 21.4%
White	11 78.6%
More than one race	0 0%
Unknown or Not Reported	0 0%
Region of Enrollment (participants) [Number]
United States	14 100%

Outcome Measures

1. Primary Outcome

Title	Overall Survival
Description	Number of participants alive at 180 days post engraftment.
Time Frame	On day +180

Outcome Measure Data

Analysis Population Description

All participants that went on study, whether completing engraftment or not.

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	14
Count of Participants [Participants]	8 57.1%

2. Secondary Outcome

Title	Hematologic Engraftment
Description	Number of participants that were able to complete engraftment by day 42.
Time Frame	On day +42

Outcome Measure Data

Analysis Population Description

Participants that went on study.

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	14
Count of Participants [Participants]	10 71.4%

3. Secondary Outcome

Title	Overall Survival
Description	Number of participants that were alive.
Time Frame	At 1 year

Outcome Measure Data

Analysis Population Description

Participants that completed engraftment. 10 participants completed engraftment by day 42 and 1 participant completed engraftment by day 46.

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	11
Count of Participants [Participants]	6 42.9%

4. Secondary Outcome

Title	Overall Survival
Description	Number of participants that were alive.
Time Frame	At 2 years

Outcome Measure Data

Analysis Population Description

Participants that completed engraftment. 10 participants completed engraftment by day 42 and 1 participant completed engraftment by day 46.

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	11
Count of Participants [Participants]	4 28.6%

5. Secondary Outcome

Title	Disease Free
Description	Number of participants that were disease free
Time Frame	At 1 year

Outcome Measure Data

Analysis Population Description

Participants that completed engraftment. 10 participants completed engraftment by day 42 and 1 participant completed engraftment by day 46.

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	11
Count of Participants [Participants]	4 28.6%

6. Secondary Outcome

Title	Disease Free
Description	Number of participants that were disease free
Time Frame	At 2 years

Outcome Measure Data

Analysis Population Description

Participants that completed engraftment. 10 participants completed engraftment by day 42 and 1 participant completed engraftment by day 46.

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	11
Count of Participants [Participants]	4 28.6%

7. Secondary Outcome

Title	Recurrence or Relapse
Description	Number of subjects that had disease recurrence
Time Frame	one year in patients post UCBT

Outcome Measure Data

Analysis Population Description

Participants that completed engraftment. 10 participants completed engraftment by day 42 and 1 participant completed engraftment by day 46.

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	11
Count of Participants [Participants]	2 14.3%

8. Secondary Outcome

Title	Recurrence or Relapse
Description	Number of subjects that had disease recurrence
Time Frame	two years post transplant

Outcome Measure Data

Analysis Population Description

Subjects who had completed engraftment

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	11
Count of Participants [Participants]	2 14.3%

9. Secondary Outcome

Title	Transplant Related Mortality
Description	Number of subjects that died because of transplant
Time Frame	On day 100 post transplant

Outcome Measure Data

Analysis Population Description

Participants that went on study

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	14
Count of Participants [Participants]	2 14.3%

10. Secondary Outcome

Title	Transplant Related Mortality
Description	Number of subjects that died because of transplant
Time Frame	On day 180 post transplant

Outcome Measure Data

Analysis Population Description

All participants that went on study

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	14
Count of Participants [Participants]	6 42.9%

11. Secondary Outcome

Title	Occurrence of Serious Infections
Description	Number of participants that had infections
Time Frame	1 year

Outcome Measure Data

Analysis Population Description

All participants that went on study

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	14
Count of Participants [Participants]	13 92.9%

12. Secondary Outcome

Title	Immune Reconstitution
Description	Immunodificency panel to see recovery of immune system. Number of participants that recovered.
Time Frame	Periodically for 2 years

Outcome Measure Data

Analysis Population Description

Data not collected, panel not done because of funding.

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	0

13. Secondary Outcome

Title	Toxicity Related to UCB Transplantation and Cytoreduction as Assessed by CTC v3.0
Description	Number of participants that experienced toxicity related to the transplant
Time Frame	by day +42

Outcome Measure Data

Analysis Population Description

Patients that received transplant

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	11
Count of Participants [Participants]	8 57.1%

14. Secondary Outcome

Title	Incidence of Acute Graft-versus-host Disease (GVHD)
Description	Number of participants that had acute GVHD
Time Frame	At 100 days

Outcome Measure Data

Analysis Population Description

All participants who went on study

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	14
Count of Participants [Participants]	11 78.6%

15. Secondary Outcome

Title	Incidence of Chronic GVHD
Description	Number of participants that have chronic GVHD. Chronic GVHD will be diagnosed and graded on clinical and histological criteria from the Center for International Blood and Marrow Transplant Research (CIBMTR)
Time Frame	At 1 year

Outcome Measure Data

Analysis Population Description

All participants that went on study

Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
Measure Participants	14
Count of Participants [Participants]	1 7.1%

Adverse Events

Time Frame	Adverse Events were collected from participant start on study to going off study up to a period of 2 years.
Adverse Event Reporting Description	Non serious events were not collected. The protocol was assessing efficacy of cord blood in transplants, therefore the research was only gathering SAEs of grade 3 or 4.
Arm/Group Title	Arm I
Arm/Group Description	PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
All Cause Mortality
	Arm I
	Affected / at Risk (%)	# Events
Total	11/14 (78.6%)
Serious Adverse Events
	Arm I
	Affected / at Risk (%)	# Events
Total	9/14 (64.3%)
Blood and lymphatic system disorders
Bone marrow cellularity - Primary graft failure	1/14 (7.1%)	1
Cardiac disorders
Supraventricular and nodal arrhythmia - Sinus tachycardia	1/14 (7.1%)	1
Hypotension	1/14 (7.1%)	1
Gastrointestinal disorders
Diarrhea	3/14 (21.4%)	4
Colitis, infectious (e.g., Clostridium difficile)	1/14 (7.1%)	1
General disorders
Death not associated with CTCAE term - Multi-organ failure	3/14 (21.4%)	3
Death not associated with CTCAE term - Death NOS	2/14 (14.3%)	2
Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L)	1/14 (7.1%)	1
Hepatobiliary disorders
Bilirubin (hyperbilirubinemia)	1/14 (7.1%)	1
Nervous system disorders
Infection with normal ANC or Grade 1 or 2 neutrophils - Brain (encephalitis, infectious)	1/14 (7.1%)	1
Product Issues
Infection with normal ANC or Grade 1 or 2 neutrophils	2/14 (14.3%)	2
Respiratory, thoracic and mediastinal disorders
Hemorrhage, pulmonary/upper respiratory - Nose	1/14 (7.1%)	1
Hypoxia	4/14 (28.6%)	5
Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)	1/14 (7.1%)	1
Other (Not Including Serious) Adverse Events
	Arm I
	Affected / at Risk (%)	# Events
Total	0/0 (NaN)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.